Ceftriaxone can be administered by deep intramuscular injection or by intravenous infusion. For IV administration, it should be infused over 30 minutes. IM injections should be given into a large muscle mass.

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bactericidal activity.

• •Hypersensitivity to ceftriaxone, any other cephalosporin, or any of the excipients.
• •Neonates (≤28 days) with hyperbilirubinemia, especially preterm neonates, due to the risk of bilirubin encephalopathy.
• •Concomitant intravenous calcium-containing solutions in neonates.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children. Reconstituted solutions should be used immediately or within specified timeframes (e.g., 6 hours at room temperature, 24 hours in a refrigerator).

In case of overdose, symptoms may include nausea, vomiting, and diarrhea. Management is primarily supportive and symptomatic. Hemodialysis or peritoneal dialysis is not effective in removing ceftriaxone from the body.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but adequate and well-controlled studies in pregnant women are lacking. Use during pregnancy only if clearly needed. Ceftriaxone is excreted in low concentrations in breast milk; caution is advised when administered to a nursing mother.